Lactitol

Summary

Lactitol (CHEMBL1661) is an approved small-molecule laxative (ATC A06AD12); indicated across 2 conditions including constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A06AD12
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 344.31 Da · C12H24O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1661
Name	Lactitol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	157355
ChEBI	CHEBI:75323
ATC	A06AD12
Molecular formula	C12H24O11
Molecular weight	344.31
InChIKey	VQHSOMBJVWLPSR-JVCRWLNRSA-N

SMILES: C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O

IUPAC name: (2S,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol

ChEBI definition: A glycosyl alditol consisting of β-D-galactopyranose and D-glucitol joined by a 1→4 glycosidic bond. It is used as a laxative, as an excipient, and as replacement bulk sweetener in some low-calorie foods.

Pharmacological roles (ChEBI): laxative, excipient, cathartic.

Also known as: BLI-400, D-lactitol, D-lactitol monohydrate, E-966, Finlac dc, Importal, INS NO.966, INS-966, Lactitol, Lactitol acm 50, Lactitol anhydrous, Lactitol hydrate

Parent form; salt/anhydrous children: CHEMBL1200429

Patent coverage: 21,261 distinct patent families (72,350 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A, 3’,5’-cyclic-AMP phosphodiesterase 4D.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE4D	5	AC50	10000	nM	CHEMBL_ACT_25185705

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02307383	PHASE2	UNKNOWN	Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers
NCT02292121	Not specified	TERMINATED	Intestinal Permeability in Obesity
NCT04579731	Not specified	COMPLETED	Development of Fecal Scoring for the Management of Fecal Impaction With Regards to Lower Urinary Tract Dysfunction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).